A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT02880371. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multicenter Phase 1b/2 study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of ARRY-382 in combination with pembrolizumab in adult patients with selected advanced solid tumors (Part A/Phase 1b); and to estimate the efficacy of the combination in three separate cohorts: 1) patients with advanced solid tumors that have progressed on prior PD-1/PD-L1inhibitors, 2) patients with platinum-resistant ovarian cancer and 3) patients with pancreatic ductal adenocarcinoma (Phase 2).
Study identification
- NCT ID
- NCT02880371
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 1, 2016 (Actual)
- Primary completion
- Sep 17, 2019 (Actual)
- Completion
- Oct 24, 2019 (Actual)
- Last update posted
- Jun 16, 2022
2016 – 2019
United States locations
- U.S. sites
- 30
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| UCLA Hematology/Oncology | Los Angeles | California | 90095 | — |
| UCLA Hematology/Oncology - Santa Monica | Santa Monica | California | 90404 | — |
| University of Colorado Denver | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Hem-Onc Associates of Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| Parkview Cancer Institute | Fort Wayne | Indiana | 46845 | — |
| Parkview Regional Medical Center | Fort Wayne | Indiana | 46845 | — |
| Parkview Research Center | Fort Wayne | Indiana | 46845 | — |
| PPG | Fort Wayne | Indiana | 46845 | — |
| Horizon Oncology Research, Inc. | Lafayette | Indiana | 47905 | — |
| Hall-Perrine Cancer Center Laboratory | Cedar Rapids | Iowa | 52403 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic Labs - Rochester Superior | Rochester | Minnesota | 55901 | — |
| Regions Cancer Care Center | Saint Paul | Minnesota | 55101 | — |
| Regions Hospital Pharmacy | Saint Paul | Minnesota | 55101 | — |
| Regions Hospital | Saint Paul | Minnesota | 55101 | — |
| HealthPartners Neurosciences Center | Saint Paul | Minnesota | 55130 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| The Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| UT Health Cancer Center | San Antonio | Texas | 78229 | — |
| UTAH Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| ARUP Laboratories, Inc. | Salt Lake City | Utah | 84108-1221 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22903 | — |
| UVA Health System | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02880371, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2022 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02880371 live on ClinicalTrials.gov.